This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Immunosuppression regimen to prevent immunotoxin neutralization	<p>A small clinical study suggests combining the immunosuppressive drugs pentostatin and cyclophosphamide could prevent neutralizing antibodies against immunotoxin treatment in cancer. In 11 patients with mesothelioma, combining the 2 drugs with the immunotoxin SS1P, which contains a portion of a bacterial exotoxin, delayed the formation of neutralizing antibodies against the toxin. In 10 evaluable patients, 3 had durable partial responses, 3 had stable disease and 4 had progressive disease. Next steps include planning additional clinical trials.</p> <p>SciBX 6(46); doi:10.1038/scibx.2013.1336 Published online Dec. 5, 2013</p>	Patent and licensing status undisclosed	<p>Hassan, R. <i>et al. Sci. Transl. Med.</i>; published online Oct. 23, 2013; doi:10.1126/scitranslmed.3006941 Contact: Raffit Hassan, National Institutes of Health (NIH), Bethesda, Md. e-mail: hassanr@mail.nih.gov</p>